March 7, 2023 — Proscia, a leading provider of digital and computational pathology solutions, today announced that PathGroup, one of the largest providers of anatomic, clinical, digital, and molecular pathology services in the United States, will advance the 150-year-old standard of diagnosis for diseases like cancer with Concentriq Dx. PathGroup is expanding its operations with Proscia’s software platform to further enhance the delivery of fast, high quality results for millions of patients, helping to better inform treatment decisions.
Up to 70% of clinical decisions depend on pathology.[1] Digital pathology shifts diagnosis from microscope to whole slide image, unlocking insights previously unseen by the human eye to realize the promise of precision medicine. It also drives powerful efficiency gains that are helping laboratories to overcome a range of systemic challenges; the number of cancer cases is expected to rise 47% between 2020 and 2040[2] while only 65% of pathology groups looking to hire could fill all open roles in 2021[3].
“Taking this next step on our journey requires a company to serve as our trusted partner and a platform that will grow across our network,” said Ben W. Davis, MD, CEO of PathGroup. “After a robust evaluation, we are thrilled that Proscia shares our vision for a fully digital future and confident that Concentriq Dx will enable us to rapidly expand upon our existing digital pathology foundation. With Proscia’s nimbleness and speed to innovation, we will leverage the latest technology, including AI, to provide the next generation of diagnosis for millions of patients.”
Concentriq Dx* is a modern pathology platform that drives routine diagnosis for laboratory networks of all sizes. By streamlining collaboration and enabling remote image viewing, it empowers pathologists to deliver higher quality results through broadened access to expertise. The platform also offers world-class interoperability with leading scanners and image analysis applications and is designed for realizing the promise of pathology’s AI-powered future to meet evolving needs.
“PathGroup’s transition to Concentriq Dx is a testament to the platform’s ability to deliver on the full promise of digital pathology at scale,” said David West, Proscia’s CEO. “Pathology data is one of healthcare’s most valuable assets, and PathGroup is now well-positioned to fully capitalize on its potential to transform patient care.”
One of the largest comprehensive pathology services providers, PathGroup currently supports more than 15,000 referring physicians and over 200 hospital customers with diversified laboratory testing services and high-touch customer service. Its team of more than 225 pathologists represents every pathology subspecialty. PathGroup operates a fully digital primary diagnosis approach at its centralized laboratory in Nashville, Tennessee.
“Digital pathology is quickly becoming synonymous with pathology,” said Steve Holloway, Company Director at Signify Research. “As leading laboratories like PathGroup grow their implementations, they continue to set a new standard of diagnosis.”
*Concentriq Dx is CE-marked under IVDR and is available for primary diagnosis in the US during the COVID-19 public health emergency.
For more information: www.proscia.com
July 31, 2024 
